Zevra Therapeutics, Inc.ZVRANASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-69.67M
↓ 152% below average
Average (9y)
$-27.60M
Historical baseline
Range
High:$10.34M
Low:$-69.67M
CAGR
+14.6%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-69.67M | -105.9% |
| 2023 | $-33.83M | -79.9% |
| 2022 | $-18.81M | -282.0% |
| 2021 | $10.34M | +624.2% |
| 2020 | $-1.97M | +91.7% |
| 2019 | $-23.76M | +56.2% |
| 2018 | $-54.22M | -62.9% |
| 2017 | $-33.28M | -9.4% |
| 2016 | $-30.41M | -49.1% |
| 2015 | $-20.40M | - |